Your browser doesn't support javascript.
loading
Significance of PR3-ANCA positivity in eosinophilic granulomatosis with polyangiitis (Churg-Strauss).
Papo, Matthias; Sinico, Renato A; Teixeira, Vítor; Venhoff, Nils; Urban, Maria-Letizia; Iudici, Michele; Mahrhold, Juliane; Locatelli, Francesco; Cassone, Giulia; Schiavon, Franco; Seeliger, Benjamin; Neumann, Thomas; Kroegel, Claus; Groh, Matthieu; Marvisi, Chiara; Samson, Maxime; Barba, Thomas; Jayne, David; Troilo, Arianna; Thiel, Jens; Hellmich, Bernhard; Monti, Sara; Montecucco, Carlomaurizio; Salvarani, Carlo; Kahn, Jean-Emmanuel; Bonnotte, Bernard; Durel, Cécile-Audrey; Puéchal, Xavier; Mouthon, Luc; Guillevin, Loïc; Emmi, Giacomo; Vaglio, Augusto; Terrier, Benjamin.
Affiliation
  • Papo M; Department of Internal Medicine, Cochin Hospital, National Referral Center for Rare Systemic Autoimmune Diseases, Paris University, Paris, France.
  • Sinico RA; Department of Medicine and Surgery, Università degli Studi di Milano-Bicocca, Milano/Monza, Italy.
  • Teixeira V; Department of Medicine, University of Cambridge, Cambridge, UK.
  • Venhoff N; Department of Rheumatology, Centro Hospitalar Universitário do Algarve, Portugal.
  • Urban ML; Department of Rheumatology and Clinical Immunology, Medical Center - University of Freiburg, Faculty of Medicine, Freiburg, Germany.
  • Iudici M; Department of Experimental and Clinical Medicine, University of Firenze, Firenze, Italy.
  • Mahrhold J; Department of Internal Medicine, Cochin Hospital, National Referral Center for Rare Systemic Autoimmune Diseases, Paris University, Paris, France.
  • Locatelli F; Rheumatology Unit, Geneva University Hospitals, Geneva, Switzerland.
  • Cassone G; Department of Internal Medicine, Rheumatology and Immunology, Vasculitis-Center Tübingen-Kirchheim, Medius Klinik Kirchheim, University of Tübingen, Kirchheim-Teck, Germany.
  • Schiavon F; Department of Rheumatology, IRCCS Policlinico S. Matteo Foundation, University of Pavia, Pavia, Italy.
  • Seeliger B; Clinical and Experimental Medicine PhD Program, Azienda USL-IRCCS di Reggio Emilia and Università di Modena and Reggio Emilia, Italy.
  • Neumann T; Operative Unit of Rheumatology, Department of Medicine DIMED, University of Padova, Padova, Italy.
  • Kroegel C; Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany.
  • Groh M; Department of Rheumatology, Clinic of Internal Medicine II I, Jena University Hospital, Jena, Germany.
  • Marvisi C; Division of Rheumatology, Immunology and Rehabilitation, Kantonsspital St Gallen, St Gallen, Switzerland.
  • Samson M; Department of Pneumology and Allergology, Clinic of Internal Medicine I, Jena University Hospital, Jena, Germany.
  • Barba T; Service de Médecine Interne, Centre de Référence des Syndromes Hyperéosinophiliques-CEREO, Hôpital Foch, Université Versailles-Saint-Quentin-en-Yvelines, Suresnes, France.
  • Jayne D; Rheumatology Unit Università di Modena and Reggio Emilia, Modena, Italy.
  • Troilo A; Department of Internal Medicine and Clinical Immunology, François-Mitterrand Teaching Hospital, University of Bourgogne-Franche-Comté, Dijon, France.
  • Thiel J; Department of Internal Medicine, Hôpital Edouard Herriot, Lyon, France.
  • Hellmich B; Department of Rheumatology, Centro Hospitalar Universitário do Algarve, Portugal.
  • Monti S; Department of Rheumatology and Clinical Immunology, Medical Center - University of Freiburg, Faculty of Medicine, Freiburg, Germany.
  • Montecucco C; Department of Rheumatology and Clinical Immunology, Medical Center - University of Freiburg, Faculty of Medicine, Freiburg, Germany.
  • Salvarani C; Rheumatology Unit, Geneva University Hospitals, Geneva, Switzerland.
  • Kahn JE; Department of Rheumatology, IRCCS Policlinico S. Matteo Foundation, University of Pavia, Pavia, Italy.
  • Bonnotte B; Department of Rheumatology, IRCCS Policlinico S. Matteo Foundation, University of Pavia, Pavia, Italy.
  • Durel CA; Azienda USL-IRCCS di Reggio Emilia, Università di Modena and Reggio Emilia.
  • Puéchal X; Service de Médecine Interne, Centre de Référence des Syndromes Hyperéosinophiliques-CEREO, Hôpital Foch, Université Versailles-Saint-Quentin-en-Yvelines, Suresnes, France.
  • Mouthon L; Department of Internal Medicine and Clinical Immunology, François-Mitterrand Teaching Hospital, University of Bourgogne-Franche-Comté, Dijon, France.
  • Guillevin L; Department of Internal Medicine, Hôpital Edouard Herriot, Lyon, France.
  • Emmi G; Department of Internal Medicine, Cochin Hospital, National Referral Center for Rare Systemic Autoimmune Diseases, Paris University, Paris, France.
  • Vaglio A; Department of Internal Medicine, Cochin Hospital, National Referral Center for Rare Systemic Autoimmune Diseases, Paris University, Paris, France.
  • Terrier B; Department of Internal Medicine, Cochin Hospital, National Referral Center for Rare Systemic Autoimmune Diseases, Paris University, Paris, France.
Rheumatology (Oxford) ; 60(9): 4355-4360, 2021 09 01.
Article in En | MEDLINE | ID: mdl-33347592
ABSTRACT

OBJECTIVES:

Only a third of patients with eosinophilic granulomatosis with polyangiitis (EGPA) are ANCA-positive, mainly directed against MPO. ANCA directed against PR3 are rarely found in EGPA. We aimed to examine the significance of PR3-ANCA in EGPA.

METHODS:

We set up a retrospective European multicentre cohort including 845 patients. Baseline characteristics and outcomes were analysed and compared according to ANCA status.

RESULTS:

ANCA status was available for 734 patients 508 (69.2%) ANCA-negative, 210 (28.6%) MPO-ANCA and 16 (2.2%) PR3-ANCA. At baseline, PR3-ANCA patients, compared with those with MPO-ANCA and ANCA-negative, less frequently had active asthma (69% vs 91% and 93%, P = 0.003, respectively) and peripheral neuropathy (31% vs 71% and 47%, P < 0.0001), more frequently had cutaneous manifestations (63% vs 38% and 34%, P = 0.03) and pulmonary nodules (25% vs 10% and 8%, P = 0.046), and lower median eosinophil count (1450 vs 5400 and 3224/mm3, P < 0.0001). Vasculitis relapse-free survival was shorter for PR3-ANCA (hazard ratio 6.05, P = 0.005) and MPO-ANCA patients (hazard ratio 1.88, P = 0.0002) compared with ANCA-negative patients.

CONCLUSION:

PR3-ANCA EGPA patients differ from those with MPO-ANCA and negative ANCA, and share clinical features with granulomatosis with polyangiitis. This suggests that PR3-ANCA EGPA could be a particular form of PR3-ANCA-associated vasculitis.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Churg-Strauss Syndrome / Granulomatosis with Polyangiitis / Antibodies, Antineutrophil Cytoplasmic Type of study: Observational_studies / Risk_factors_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Rheumatology (Oxford) Journal subject: REUMATOLOGIA Year: 2021 Type: Article Affiliation country: France

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Churg-Strauss Syndrome / Granulomatosis with Polyangiitis / Antibodies, Antineutrophil Cytoplasmic Type of study: Observational_studies / Risk_factors_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Rheumatology (Oxford) Journal subject: REUMATOLOGIA Year: 2021 Type: Article Affiliation country: France